Medullary Thyroid Cancer: Clinical Trials

40 trials for Medullary Thyroid Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

11 completed, 6 active not recruiting, 6 unknown, 5 recruiting. 13 Phase 2, 11 Phase 1, 6 Not applicable, 3 Phase 3, 3 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 213Active not recruiting 3, Terminated 3, Unknown 3, Completed 2, Recruiting 1, Withdrawn 1
Phase 111Unknown 3, Active not recruiting 2, Completed 2, Terminated 2, Not yet recruiting 1, Recruiting 1
Not applicable6Completed 3, Recruiting 2, Terminated 1
Phase 33Active not recruiting 1, Completed 1, Withdrawn 1
Phase 43Active not recruiting 1, Recruiting 1, Unknown 1

Follow Medullary Thyroid Cancer: new trials by email Literature Review of Medullary Thyroid Cancer trials Research Report on Medullary Thyroid Cancer

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
211At-MABG in Adults With Advanced Neuroendocrine Cancers
1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated - Pheochromocytoma, Paraganglioma
Phase 1Not yet recruitingUniversity of Pennsylvania162026-12-012026-10-07
Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer
Phase 1 / Phase 2RecruitingUniversity of Arizona302025-09-082026-10-06
A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study
Medullary Thyroid Cancer
Not yet recruitingPower Life Sciences Inc.5002024-11-012023-10-12
Predictive Factors for Medullary Thyroid Cancer Aggressiveness
Total Thyroidectomy - Medullary Thyroid Cancer
CompletedAristotle University Of Thessaloniki5002024-03-012025-01-03
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001)
individualized mRNA neoantigen vaccine (mRNA-0523-L001) - Adrenal Cortical Carcinoma, Medullary Thyroid Cancer
Not applicableRecruitingShanghai Jiao Tong University School of Medicine212024-01-132026-04-09
A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).
Pralsetinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer
Phase 3WithdrawnHoffmann-La Roche2023-11-302024-01-05
68Ga-TCR-FAPI PET/CT Guided Precision Surgery for MTC
Surgery - Medullary Thyroid Cancer, Prositron Emission Tomography
Not applicableRecruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences502023-10-012024-02-26
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Anlotinib Hydrochloride Capsule - Medullary Thyroid Cancer
Phase 4RecruitingChia Tai Tianqing Pharmaceutical Group Co., Ltd.3602023-06-192023-07-25
A Study of TY-1091 in Patients With Advanced Solid Tumors
TY-1091 - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2UnknownTYK Medicines, Inc2482023-04-242024-01-30
Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer
18F-PSMA-1007 - Medullary Thyroid Cancer, Medullary Thyroid Carcinoma
Not applicableCompletedUniversity Medical Center Groningen82022-08-192025-06-24
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients
Neuroendocrine Neoplasm, Neuroendocrine Neoplasm of Gastrointestinal Tract
RecruitingUniversidad Nacional Autonoma de Mexico7502022-08-032024-07-26
Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor
SY-5007 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2UnknownShouyao Holdings (Beijing) Co. LTD1842021-04-232023-04-12
Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal Amyloidosis
Amyloid, Medullary Thyroid Cancer
UnknownThe Leeds Teaching Hospitals NHS Trust102021-02-012021-02-18
Thermal Ablation of Cervical Metastases From Thyroid Carcinoma
Laser ablation, Cryoablation, Radiofrequency ablation - Thyroid Neoplasia, Well-Differentiated Thyroid Cancer
Not applicableCompletedInstituto do Cancer do Estado de São Paulo842020-12-222026-09-22
A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Selpercatinib - Solid Tumor, Medullary Thyroid Cancer
Phase 2Active not recruitingEli Lilly and Company772020-03-162026-08-07
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Selpercatinib, Cabozantinib, Vandetanib - Medullary Thyroid Cancer
Phase 3Active not recruitingLoxo Oncology, Inc.2912020-02-112026-03-19
Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations
TPX-0046 - Non Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2TerminatedTurning Point Therapeutics, Inc.412019-12-062024-06-13
Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Ponatinib - Medullary Thyroid Cancer
Phase 2WithdrawnAntonio Fojo2019-07-262021-10-13
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
Selpercatinib - Medullary Thyroid Cancer, Infantile Myofibromatosis
Phase 1 / Phase 2Active not recruitingEli Lilly and Company362019-06-132026-01-06
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
LOXO-292 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Phase 1 / Phase 2Active not recruitingEli Lilly and Company8572017-05-022026-04-16

Showing 20 of 40. Sign in to see all of them.

Narrower conditions

Carcinoma, Medullary (40)  ·  Thyroid Neoplasms (10)  ·  Carcinoma, Non-Small-Cell Lung (9)  ·  Colonic Neoplasms (5)  ·  Lung Neoplasms (4)  ·  Neoplasms (4)  ·  Neuroendocrine Tumors (4)  ·  Thyroid Cancer, Papillary (4)  ·  Breast Neoplasms (3)  ·  Bronchial Neoplasms (3)  ·  Carcinoma, Bronchogenic (3)  ·  Endocrine Gland Neoplasms (3)  ·  Endocrine System Diseases (3)  ·  Head and Neck Neoplasms (3)  ·  Lung Diseases (3)

Broader conditions

Neoplasms, Ductal, Lobular, and Medullary (40)  ·  Adenocarcinoma (39)  ·  Carcinoma (39)  ·  Carcinoma, Neuroendocrine (39)  ·  Neoplasms by Histologic Type (39)  ·  Neoplasms, Germ Cell and Embryonal (39)  ·  Neoplasms, Glandular and Epithelial (39)  ·  Neoplasms, Nerve Tissue (39)  ·  Neuroectodermal Tumors (39)  ·  Neoplasms (36)  ·  Neuroendocrine Tumors (36)  ·  Neoplasms by Site (15)  ·  Endocrine Gland Neoplasms (11)  ·  Endocrine System Diseases (11)  ·  Head and Neck Neoplasms (8)

Interventions

selpercatinib (5)  ·  cabozantinib (4)  ·  vandetanib (4)  ·  pralsetinib (3)  ·  Calcium Aluminosilicate (1)  ·  Cryoelectron Microscopy (1)  ·  Cryosurgery (1)  ·  Dexamethasone (1)  ·  Everolimus (1)  ·  Ga(III)-DOTATOC (1)  ·  Laser Therapy (1)  ·  Lithium Carbonate (1)  ·  Lutetium-177 (1)  ·  Omeprazole (1)  ·  Radiofrequency Ablation (1)

Sponsors

Eli Lilly and Company (4)  ·  Exelixis (2)  ·  Hoffmann-La Roche (2)  ·  Sanofi (2)  ·  AbbVie (1)  ·  Antonio Fojo (1)  ·  Aristotle University Of Thessaloniki (1)  ·  Blueprint Medicines Corporation (1)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1)  ·  Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)  ·  Federico II University (1)  ·  Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1)  ·  Genzyme, a Sanofi Company (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  Institut Claudius Regaud (1)

Countries

United States (18)  ·  China (10)  ·  Italy (10)  ·  France (8)  ·  Spain (8)  ·  South Korea (7)  ·  Australia (6)  ·  Canada (6)  ·  Germany (6)  ·  United Kingdom (6)  ·  Brazil (5)  ·  Israel (5)  ·  Poland (5)  ·  Belgium (4)  ·  Japan (4)

Top investigators

Annamaria Colao (1)  ·  Antonio Fojo, MD (1)  ·  Charles Hsu, MD (1)  ·  Fernanda Vaisman, MD, PhD (1)  ·  Herbert Chen, MD (1)  ·  James Moor, FRCS (1)  ·  Johannes Czernin, MD (1)

Results publications

PMID 36657661, PMID 37934000, PMID 25117183, PMID 28473600, PMID 29572709, PMID 32372416, PMID 32846060, PMID 32846061, PMID 34088726, PMID 34118197, PMID 34118198, PMID 34292174, PMID 35403447, PMID 35715405, PMID 35923928, PMID 35930972, PMID 35962206, PMID 35969032, PMID 36056624, PMID 36062046, PMID 36108661, PMID 36122315, PMID 36996322, PMID 37265412, PMID 37282666, PMID 37315261, PMID 37655205, PMID 37870969, PMID 37916501, PMID 38009200, PMID 38661071, PMID 39085487, PMID 39094065, PMID 39471424, PMID 39489747, PMID 39694978, PMID 39759832, PMID 39983053, PMID 40617171, PMID 40639400, PMID 41886723, PMID 42337037, PMID 42874021

NIH funding

2019 (2), 2016 (1), 2017 (1), 2023 (1), R01CA300202 (1)